October 3, 2014Open Access

Efficacy and Safety of Treatment With an Anti-M2e Monoclonal Antibody in Experimental Human Influenza

Key Points

Key points are not available for this paper at this time.

Abstract

These data indicate that TCN-032 may provide immediate immunity and therapeutic benefit in influenza A infection, with no apparent emergence of resistant virus. TCN-032 was safe with no evidence of immune exacerbation based on serum cytokine expression. Clinicaltrials.gov registry number. NCT01719874.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Ramos et al. (Fri,) studied this question.

synapsesocial.com/papers/69d8da562c39562886ae30a3 https://doi.org/https://doi.org/10.1093/infdis/jiu539

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza1999 · 558 citations
2Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions1988 · 525 citations
3Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments2009 · 199 citations
4Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin2007 · 386 citations
5Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses2010 · 140 citations

Bookmark

View Full Paper